8-K: Ionis Olezarsen Shines in Phase 3 sHTG Trials

Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies for olezarsen, demonstrating significant reductions in triglycerides and acute pancreatitis events in severe hypertriglyceridemia patients.

Summary

• Olezarsen achieved a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% in people with severe hypertriglyceridemia (sHTG).
• The studies demonstrated a highly statistically significant 85% reduction in acute pancreatitis events (p=0.0002) compared to placebo.
• Olezarsen exhibited a favorable safety and tolerability profile, with adverse events generally balanced across treatment groups and serious adverse events occurring less frequently in olezarsen groups.
• The CORE and CORE2 studies represent the largest pivotal program for sHTG, enrolling nearly 1,100 patients who remained on standard of care lipid-lowering therapy.
• Both 80 mg and 50 mg monthly doses of olezarsen met the primary endpoint of reducing fasting triglyceride levels at six months.
• Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration by the end of 2025.

Sentiment

Score: 9

Explanation: The results are overwhelmingly positive, demonstrating significant efficacy in both primary and secondary endpoints, a favorable safety profile, and addressing a critical unmet medical need. The potential for a new treatment standard and a third independent launch for Ionis are strong indicators of future success.

Positives

• Achieved up to a 72% placebo-adjusted mean reduction in fasting triglycerides (p<0.0001 for all doses in both CORE and CORE2 studies).
• Demonstrated an 85% reduction in acute pancreatitis events (p=0.0002), marking the first and only time this has been achieved for sHTG treatment.
• Exhibited a favorable safety and tolerability profile, with serious adverse events occurring less frequently in the olezarsen groups compared to placebo.
• More than 90% of patients who completed CORE and CORE2 chose to continue into the open-label extension study, indicating strong patient confidence and tolerability.
• The CORE and CORE2 studies constitute the largest pivotal program for sHTG, involving nearly 1,100 patients.
• Positions Ionis to establish a new treatment standard for the many people with sHTG at risk of debilitating acute pancreatitis attacks.
• If approved, olezarsen for sHTG will be Ionis' third independent launch in under two years and its first launch in a prevalent population.

Negatives

• Injection site reactions, mostly mild, were the most common adverse event and occurred more frequently in the olezarsen groups compared to placebo.

Risks

• Risks and uncertainties are inherent in the process of discovering, developing, and commercializing medicines that are safe and effective for human therapeutics.
• Risks are involved in the endeavor of building a business around such medicines.
• Forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause actual results to differ materially from expectations.
• Additional factors that could cause actual results to differ materially are disclosed in Ionis' filings with the SEC, including the Risk Factors section in its most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q.

Future Outlook

Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration by the end of 2025. Detailed data from the CORE and CORE2 studies will be presented at an upcoming medical conference. If approved, olezarsen for sHTG is expected to be Ionis' third independent launch in under two years and its first launch in a prevalent population, marking a major step forward in delivering transformative care.

Management Comments

• "These data are groundbreaking, demonstrating that olezarsen is the first therapy for sHTG to significantly reduce acute pancreatitis events." Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis.
• "Despite current standard of care and lifestyle changes, people with sHTG – who could have triglyceride levels reaching into the thousands – remain vulnerable to unpredictable and life-threatening acute pancreatitis attacks. These results reinforce our confidence that olezarsen has the potential to change the sHTG treatment paradigm." Sam Tsimikas, M.D.
• "Building on our success in familial chylomicronemia syndrome, the exceptional CORE and CORE2 results position Ionis to set a new treatment standard for the many people with sHTG who are at risk of debilitating acute pancreatitis attacks." Brett P. Monia, Ph.D., chief executive officer, Ionis.
• "If approved, olezarsen for sHTG will mark our third independent launch in under two years and our first launch in a prevalent population, marking a major step forward in delivering transformative care to those who need it most." Brett P. Monia, Ph.D.

Industry Context

Severe hypertriglyceridemia (sHTG), defined by triglyceride levels ≥500 mg/dL, affects approximately 3 million people in the U.S., with over 1 million considered high risk. This condition significantly increases the risk of acute pancreatitis, a medical emergency often requiring hospitalization. Current standard of care therapies and lifestyle modifications are often insufficient to consistently lower triglyceride levels or reduce risks for all patients. Olezarsen's demonstrated ability to significantly reduce acute pancreatitis events is a first for sHTG treatment, addressing a critical unmet medical need and potentially establishing a new treatment paradigm in a market with a substantial patient population.

Comparison to Industry Standards

• Olezarsen achieved an 85% reduction in acute pancreatitis events, which is the first and only time such a reduction has been achieved for the treatment of sHTG.
• The CORE and CORE2 studies constitute the largest pivotal program for sHTG, enrolling nearly 1,100 patients, demonstrating a robust clinical development effort.
• Current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients, highlighting olezarsen's potential to fill a significant treatment gap.
• Olezarsen is already approved in the U.S. as TRYNGOLZA for familial chylomicronemia syndrome (FCS), demonstrating prior success with a related RNA-targeted medicine.

Stakeholder Impact

• Shareholders: Highly positive impact due to successful pivotal clinical trials, potential for new drug approval in a significant market, and strong commercial prospects.
• Patients with sHTG: Extremely positive impact, as olezarsen offers a new, highly effective treatment option that significantly reduces life-threatening acute pancreatitis events, addressing a critical unmet medical need.
• Healthcare Providers: Provides a new, potentially transformative treatment option for managing sHTG and preventing its severe complications.
• Employees: Positive impact on morale and job security due to successful drug development and anticipated commercialization, reinforcing Ionis' leadership in RNA-targeted medicines.

Next Steps

• Submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration by the end of 2025.
• Present detailed data from the CORE and CORE2 studies at an upcoming medical conference.

Key Dates

Recommendation

The Phase 3 results for olezarsen are exceptionally strong, demonstrating highly statistically significant reductions in both triglycerides and, critically, acute pancreatitis events, a first for sHTG treatment. This addresses a significant unmet medical need in a prevalent population of 3 million U.S. patients. The favorable safety profile and high patient retention in the extension study further bolster confidence. With an sNDA submission planned by year-end and potential for a third independent launch, these results position Ionis for substantial commercial success and market leadership in sHTG, making it a compelling investment opportunity.

Keywords

severe hypertriglyceridemia, sHTG, olezarsen, Phase 3, CORE study, CORE2 study, triglycerides, acute pancreatitis, RNA-targeted medicine, Ionis Pharmaceuticals, FDA, sNDA, cardiometabolic disease